Don't forget the turnover/sales for EPPuse after EMA approval. In Europa there are apr. 3.500 EPP patients.
3.500 x apr. € 30.000 = 105 mln.
If only half of the patients are going to use Scenesse Clinuvel will be a profitable biotechcompany.
nomura "maa review should complete by start 4q, page-8
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |